Gbaa Terry, Adebisi Simeon, Bolodeoku John, Dogoh Faeren, Gav Terna
Department of Chemical Pathology, Benue State University Teaching Hospital, Makurdi, Benue, Nigeria.
Lipid Clinic, Department of Cardiology, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom *Email:
Qatar Med J. 2025 Sep 10;2025(3):82. doi: 10.5339/qmj.2025.82. eCollection 2025.
Thyroglobulin has been identified as a marker for thyroid cancer monitoring. However, researchers have proposed and employed it as a biomarker to assess iodine-dependent thyroid dysfunction during pregnancy. Pregnancy is a hyperdynamic state that significantly strains the mother's iodine stores due to the demands of the foetus. This study combined thyroglobulin and thyroid function tests to see their impact on identifying more patients who are at risk for thyroid disorders in pregnancy. The aim of the study was to determine thyroglobulin as an adjunct biomarker in thyroid function assessment in pregnancy.
Participants were across five centers, and the study was conducted over a period of 9 months (June 2019-February 2020). The study comprised a cohort of 250 pregnant women who were attending their antenatal clinic visits. These participants were selected randomly using a table of random numbers. Blood samples were taken and analyzed using immunoassay techniques. The data were analyzed using Statistical Package for Social Sciences (SPSS), version 21 (IBM, Chicago, IL).
Thyroid-stimulating hormone (TSH) assay only identified 35 (14%) participants, whereas the combination of the TSH and Tg assays identified 50 (20%) participants. Thyroglobulin and free thyroxine measurements revealed the presence of hyperthyroidism in 15 (9.6%) and hypothyroidism in 8 (3.2%). Using both TSH and thyroglobulin, we identified 54 (21.6%) participants as having thyroid dysfunction, with a higher prevalence of 40 (16%) hypothyroid participants compared to 14 (5.6%) hyperthyroid participants.
Thyroglobulin is valuable during pregnancy, with the ability to reflect iodine status as a sensitive marker in identifying early thyroid dysfunction.
甲状腺球蛋白已被确定为甲状腺癌监测的标志物。然而，研究人员已提出并将其用作评估孕期碘依赖性甲状腺功能障碍的生物标志物。孕期是一种高动力状态，由于胎儿的需求，会极大地消耗母亲的碘储备。本研究结合甲状腺球蛋白和甲状腺功能测试，以观察它们对识别更多孕期甲状腺疾病风险患者的影响。该研究的目的是确定甲状腺球蛋白作为孕期甲状腺功能评估中的辅助生物标志物。
参与者来自五个中心，研究为期9个月（2019年6月至2020年2月）。该研究纳入了250名前来产前门诊就诊的孕妇队列。这些参与者使用随机数字表随机选取。采集血样并使用免疫测定技术进行分析。数据使用社会科学统计软件包（SPSS）21版（IBM，伊利诺伊州芝加哥）进行分析。
促甲状腺激素（TSH）检测仅识别出35名（14%）参与者，而TSH和Tg检测相结合识别出50名（20%）参与者。甲状腺球蛋白和游离甲状腺素测量显示，15名（9.6%）存在甲状腺功能亢进，8名（3.2%）存在甲状腺功能减退。同时使用TSH和甲状腺球蛋白，我们确定54名（21.6%）参与者存在甲状腺功能障碍，其中甲状腺功能减退参与者患病率较高，为40名（16%），而甲状腺功能亢进参与者为14名（5.6%）。
甲状腺球蛋白在孕期很有价值，能够作为反映碘状态的敏感标志物来识别早期甲状腺功能障碍。
